Heart failure & cardiomyopathiesCohort study
Arrhythmic genotypes in dilated cardiomyopathy and risk of advanced heart failure
- Retrospective cohort study
- multicentre
Authors' conclusion
Patients with high-risk arrhythmic genotypes also experience more AHF events
Study context
- Population
- Genotyped dilated cardiomyopathy (DCM) patients from 19 Spanish centres
- Participants
- 1,203 patients · 19 Spanish centres
- Exposure
- High-risk arrhythmic genotypes vs other DCM genotypes
- High-risk arrhythmicn = 185
- TTNn = 193
- Other genesn = 134
- Gen-n = 691
- Outcome
- Composite of AHF events (ventricular assist device implantation, heart transplant, AHF-related mortality)
- Follow-up
- Median 5.7 years (IQR 2.9-9.1 years)
Main finding
AHF events · median 5.7 years
Hazard ratio
1.85
95% CI 1.31–2.61
Events by group
High-risk arrhythmic vs other groups
HR 1.85 (95% CI 1.31–2.61)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| Malignant ventricular arrhythmias (MVA) · median follow-up 5.7 years | 2.52 (1.81–3.51) | |
| 0.20.5125Hazard ratio (log scale) |
- Malignant ventricular arrhythmias (MVA) — MVA occurred in 55 patients
- 29.7%
Malignant ventricular arrhythmias (MVA) · median follow-up 5.7 years
- High-risk arrhythmic genotype and late gadolinium enhancement independent predictors of MVA
Original publication
Arrhythmic genotypes in dilated cardiomyopathy and risk of advanced heart failure. Eur Heart J. Published 29 August 2025. doi:10.1093/eurheartj/ehaf605
Summarised from the published abstract; every number is checked against it